Revisions to USP33-NF28 2S

Published June 2010

General Chapters Monographs:

Monograph Title	Monograph Section	Scientific Liaison
<1> INJECTIONS PF 35(5) Pg. 1214	PACKAGING	Desmond Hunt
<11> USP REFERENCE STANDARDS PF 35(5) Pg. 1217	USP Andrographolide RS, USP 3-Acetyl-11-keto-beta-Boswellic Acid RS, USP Boswellia Serrata Extract RS, USP Clenbuterol Hydrochloride RS, USP Clenbuterol Related Compound B RS, USP Cyclophosphamide Related Compound A RS, USP Cyclophosphamide Related Compound C RS, USP Cyclophosphamide Related Compound C RS, USP Cyclophosphamide Related Compound C RS, USP Cyclophosphamide Related Compound D RS, USP Powdered Ashwagandha Extract RS, USP Balsalazide Disodium RS, USP Docetaxel RS, USP Balsalazide Related Compound A RS, USP Docetaxel Identification RS, USP Balsalazide Related Compound B RS, USP Dofetilide RS, USP Benzethonium Chloride RS, USP Dofetilide Related Compound A RS, USP Ensulizole RS, USP L-Glutamic Acid, Hydrochloride RS, USP Orlistat RS., USP Hydromorphone Related Compound A RS, USP rHuman Interleukin 4 RS, USP Orlistat Related Compound D RS, USP Lactobionic Acid RS, USP Levetiracteam RS, USP Methacrylic Acid and Ethyl Acrylate Copolymer (1:1) RS, USP Levetiracetam Related Compound B RS, USP Methacrylic Acid and Methyl Methacrylate Copolymer (1:1) RS, USP Levetiracetam Related Compound B RS, USP Methacrylic Acid and Methyl Methacrylate Copolymer (1:2) RS, USP Levetiracetam Related Compound B RS, USP Methacrylic Acid and Methyl Methacrylate Copolymer (1:2) RS, USP Levetiracetam Racemic Mixture RS, USP Methylbenzethonium Chloride RS, USP Phenylbenzimidazole Sulfonic Acid RS, USP Risperidone Related Compounds	Barbara Jones

Mixture RS, USP Methylpyrrolidone RS, USP Withanolide A RS, USP Morphine Related Compound B RS, USP Withanoside IV RS, USP Orlistat Related Compound A RS, USP Zolpidem Impurities Mixture RS, USP Orlistat Related Compound B RS, USP Orlistat Related Compound C RS, USP Orlistat Related Compound E RS, USP Polydextrose RS, USP Propanolamine RS, USP Ractopamine Hydrochloride RS, USP Raspberry Ketone RS, USP Raspberry Alcohol RS, USP Riluzole RS, USP Riluzole Related Compound A RS, USP Tartaric Acid RS, USP Tramadol Related Compound B RS

<92> GROWTH FACTORS AND CYTOKINES USED IN CELL THERAPY MANUFACTURING PF 35(4) Pg. 915 Title, DEFINITION/Introduction, IDENTIFICATION/A., IDENTIFICATION/B./Phosphate buffered saline, IDENTIFICATION/B./Laemmli sample buffer, reducing, IDENTIFICATION/B./Laemmli sample buffer, nonreducing, IDENTIFICATION/B./Standard stock solution, IDENTIFICATION/B./Standard solution, IDENTIFICATION/B./Standard solution, reducing, IDENTIFICATION/B./Standard solution, nonreducing, IDENTIFICATION/B./Sample stock solution, IDENTIFICATION/B./Sample solution, IDENTIFICATION/B./Sample solution, reducing, IDENTIFICATION/B./Sample solution, nonreducing, IDENTIFICATION/B./Analysis/Samples, IDENTIFICATION/B./Western blotting, IDENTIFICATION/B./Acceptance criteria, ASSAY/Purity:/Molecular weight marker, ASSAY/Purity:/Phosphate buffered saline, ASSAY/Purity:/Laemmli sample buffer, nonreducing, ASSAY/Purity:/Laemmli sample buffer, reducing, ASSAY/Purity:/Sample stock solution, ASSAY/Purity:/Sample solution 1, ASSAY/Purity:/Sample solution 2, ASSAY/Purity:/Control A stock solution, ASSAY/Purity:/Control A solution 1,

ASSAY/Purity:/Control A solution 2, ASSAY/Purity:/Control B stock solution, ASSAY/Purity:/Control B solution 1, Fouad Atouf

ASSAY/Purity:/Control B solution 2, ASSAY/Purity:/Electrophoretic conditions/Mode, ASSAY/Purity:/Electrophoretic conditions/Stacking gel, ASSAY/Purity:/Electrophoretic conditions/Resolving gel, ASSAY/Purity:/Electrophoretic conditions/Run conditions, ASSAY/Purity:/Electrophoretic conditions/Protein detection, ASSAY/Purity:/Analysis/Samples, ASSAY/Purity:/Acceptance criteria, ASSAY/Protein Content:/Sample solution, ASSAY/Protein Content:/Blank, ASSAY/Protein Content:/Spectroscopic conditions/Mode, ASSAY/Protein Content:/Spectroscopic conditions/Pathlength, ASSAY/Protein Content:/Spectroscopic conditions/Analytical wavelength, ASSAY/Protein Content:/Analysis/Samples, SPECIFIC TESTS/Bioidentity:/RPMI 1640 medium with L-glutamine, SPECIFIC TESTS/Bioidentity:/Growth medium, SPECIFIC TESTS/Bioidentity:/Assay medium, SPECIFIC TESTS/Bioidentity:/Phosphate buffered saline, SPECIFIC TESTS/Bioidentity:/Resazurin solution, SPECIFIC TESTS/Bioidentity:/Standard stock solution, SPECIFIC TESTS/Bioidentity:/Standard solutions, SPECIFIC TESTS/Bioidentity:/Sample stock solution, SPECIFIC TESTS/Bioidentity:/Sample solutions, SPECIFIC TESTS/Bioidentity:/Control solution, SPECIFIC TESTS/Bioidentity:/Cell culture preparation, SPECIFIC TESTS/Bioidentity:/Analysis/Samples, **SPECIFIC** TESTS/Bioidentity:/Acceptance criteria, SPECIFIC TESTS/Sterility Tests <71>, SPECIFIC TESTS/Bacterial Endotoxins Test <85>, ADDITIONAL REQUIREMENTS/Packaging and Storage, ADDITIONAL REQUIREMENTS/Labeling, ADDITIONAL REQUIREMENTS/USP

<228> ETHYLENE OXIDE AND

Title, Introduction, Method I, Method II

Reference Standards <11>

Hong Wang

DIOXANE PF 35(4) Pg. 917 <331> AMPHETAMINE ASSAY Title, USP REFERENCE STANDARDS Ravi Ravichandran PF 35(4) Pg. 920 <11>, STANDARD PREPARATION, ASSAY PREPARATION, PREPARATION OF CHROMATOGRAPHIC COLUMN, PROCEDURE INTRODUCTION **Desmond Hunt** <381> ELASTOMERIC CLOSURES FOR INJECTIONS PF 35(5) Pg. 1225 <645> WATER CONDUCTIVITY Introduction, INSTRUMENT Antonio Hernandez-Cardoso PF 35(5) Pg. 1226 SPECIFICATIONS AND OPERATING PARAMETERS, BULK WATER, PACKAGEDSTERILE WATER <670> CONTAINERS --Title, Introduction, **Desmond Hunt** AUXILIARY COMPONENTS PF PHARMACEUTICAL COIL 34(6) Pg. 1533 <741> MELTING RANGE OR Introduction, PROCEDURE FOR Antonio Hernandez-Cardoso TEMPERATURE PF 35(4) Pg. 925 CLASS I, APPARATUS II, PROCEDURE FOR CLASS IA, APPARATUS II, PROCEDURE FOR CLASS IB, APPARATUS II Title, INTRODUCTION, TABLETS Robert Lafaver <1059> EXCIPIENT PERFORMANCE PF 35(5) Pg. AND CAPSULES, ORAL LIQUIDS, SEMISOLIDS, TOPICALS, AND 1228 SUPPOSITORIES, PARENTERALS, **AEROSOLS CLASSIFICATION OF** Radhakrishna Tirumalai <1072> DISINFECTANTS AND DISINFECTANTS, SELECTION OF A ANTISEPTICS PF 35(5) Pg. 1250 DISINFECTANT FOR USE IN A **PHARMACEUTICAL**

MANUFACTURING ENVIRONMENT, THEORETICAL DISCUSSION OF DISINFECTANT ACTIVITY,

MECHANISM OF DISINFECTANT

ACTIVITY, MICROBIAL

RESISTANCE TO DISINFECTANTS, DISINFECTANT CHALLENGE TESTING, DISINFECTANTS IN A **CLEANING AND SANITIZATION**

PROGRAM

<1075> GOOD COMPOUNDING PRACTICES PF 35(4) Pg. 942

Title, Introduction, APPLICABLE DEFINITIONS, RESPONSIBILITIES OF THE COMPOUNDER, TRAINING, PROCEDURES AND DOCUMENTATION, DRUG

Rick Schnatz

COMPOUNDING FACILITIES, DRUG COMPOUNDING EQUIPMENT,

COMPONENT SELECTION REQUIREMENTS, PACKAGING AND DRUG PREPARATION CONTAINERS, COMPOUNDING CONTROLS, LABELING, RECORDS AND REPORTS, COMPOUNDING FOR A PRESCRIBER'S OFFICE USE, COMPOUNDING VETERINARIAN **PRODUCTS**

<1086> IMPURITIES IN OFFICIAL ARTICLES PF 35(5) Pg. 1254

Title, INTRODUCTION, INITIAL IND FILING, DRUG SUBSTANCE, NDA FILING, DRUG PRODUCT, POST NDA APPROVAL, ANDA FILING, **DEFINITIONS**

Antonio Hernandez-Cardoso

<1117> MICROBIOLOGICAL **BEST LABORATORY** PRACTICES PF 35(4) Pg. 945

INTRODUCTION, MEDIA PREPARATION AND QUALITY CONTROL, MAINTENANCE OF MICROBIOLOGICAL CULTURES, MAINTENANCE OF LABORATORY EQUIPMENT, LABORATORY LAYOUT AND OPERATIONS, SAMPLE HANDLING, MICROBIOLOGICAL MEDIA INCUBATION TIMES, TRAINING OF PERSONNEL, LABORATORY RESOURCES, DOCUMENTATION, MAINTENANCE OF LABORATORY RECORDS, INTERPRETATION OF ASSAY RESULTS

Radhakrishna Tirumalai

<1211> STERILIZATION AND STERILITY ASSURANCE OF COMPENDIAL ARTICLES PF 35(4) Pg. 952

Introduction, METHODS OF STERILIZATION, STERILITY TESTING OF LOTS, PERFORMANCE, OBSERVATION, AND **INTERPRETATION**

Radhakrishna Tirumalai

<1231> WATER FOR PHARMACEUTICAL PURPOSES PF 35(5) Pg. 1310

INTRODUCTION, TYPES OF WATER, Antonio Hernandez-Cardoso CHEMICAL CONSIDERATIONS

Fouad Atouf

<1235> VACCINES FOR HUMAN USE -- GENERAL CONSIDERATIONS PF 35(4) Pg. 960

Title, INTRODUCTION, OVERALL MANUFACTURING PLAN. SEED LOT SYSTEMS, FERMENTATION AND CELL CULTURE MEDIA, PROPAGATION AND HARVEST, PURIFICATION, INTERMEDIATES, FINAL BULK, FINAL CONTAINER, **EVALUATING THE STABILITY OF** VACCINES, NOMENCLATURE, LABELING, LOT RELEASE TESTING,

APPENDIX 1. TYPES OF VACCINES CURRENTLY LICENSED IN THE U.S.

(EXAMPLES), APPENDIX 2.

SELECTED REGULATORY DOCUMENTS, GLOSSARY

<2040> DISINTEGRATION AND DISSOLUTION OF DIETARY SUPPLEMENTS PF 35(4) Pg. 984 DISINTEGRATION, DISSOLUTION

Natalia Davydova

Yoshiyuki Tokiwa

<2750> MANUFACTURING PRACTICES FOR DIETARY SUPPLEMENTS PF 35(5) Pg. 1319 Introduction, GENERAL PROVISIONS, ORGANIZATION AND PERSONNEL, GROUNDS, BUILDINGS, AND FACILITIES, EQUIPMENT AND UTENSILS, RAW MATERIALS, PRODUCT CONTAINERS, AND CLOSURES, PRODUCTION AND PROCESS CONTROLS, LABELING

CONTROL OPERATIONS, RECORDS AND REPORTS, RETURNED AND SALVAGED PRODUCTS, GLOSSARY

AND PACKAGING, QUALITY

General Chapters Monographs: